Please login to the form below

Not currently logged in
Email:
Password:

Nycomed wins EC approval for Instanyl

The EC has granted Nycomed marketing authorisation for its Instanyl single-dose nasal spray

The European Commission (EC) has granted Nycomed marketing authorisation for its Instanyl single-dose nasal spray.

The spray is approved for the management of breakthrough pain in cancer patients, and was first approved in Europe as a multi-dose nasal spray in 2009.

The launch of the single-dose spray will provide greater flexibility to the patient and help to manage dose titration and dose modification, as well as enabling easier tracking of patient's use of rescue medication, according to Nycomed.

Guido Oelkers, executive vice president at the company, said: "Development of the Instanyl single-dose nasal spray further demonstrates Nycomed's commitment to innovation in areas of clear medical need. Over half a million cancer patients are suffering from breakthrough pain in Europe. The Instanyl single-dose nasal spray will add flexibility to the managing of their pain."

The single-dose nasal spray will be available in 50 µg, 100 µg, and 200 µg doses.

4th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics